NCT06257680 is a Phase 1 clinical trial of ReT01 ACT in Advanced Solid Tumor, sponsored by Aeonvital Biomedicine.

Who is sponsoring NCT06257680?

NCT06257680 is sponsored by Aeonvital Biomedicine.

What drugs are being tested in NCT06257680?

Interventions in NCT06257680: ReT01 ACT.

What condition does NCT06257680 study?

NCT06257680 studies Advanced Solid Tumor.

Is NCT06257680 still recruiting?

NCT06257680 is currently recruiting now. Last updated 31 July 2024.

Last reviewed 2024-07-31 · How we verify

NCT06257680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

Recruiting now Phase 1 Last updated 31 July 2024

What this trial tests

Phase 1 trial testing ReT01 ACT in Advanced Solid Tumor in 15 participants. Currently enrolling.

Timeline

8 April 2024

Primary endpoint
18 February 2025

18 February 2027

Quick facts

Lead sponsor	Aeonvital Biomedicine
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	8 April 2024
Primary completion	18 February 2025
Estimated completion	18 February 2027
Sites	1 location across China

Drugs / interventions tested

ReT01 ACT — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Aeonvital Biomedicine — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06257680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aeonvital Biomedicine
Last refreshed: 31 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06257680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing